24 sources·Health

Biden Administration Proposes $35 Billion Coverage for Anti-Obesity Drugs Amid Challenges from Incoming Trump Officials

The Biden administration's rule seeks to allow Medicare and Medicaid coverage for anti-obesity medications, but faces potential opposition and budget concerns.

29%

54%

17%

The distribution of story sources: left-leaning (blue), center (light gray), and right-leaning (red).

Mostly Reliable

The underlying sources are generally reliable but sometimes include opinion, propaganda, or minor inaccuracies.

Balanced

The underlying sources are either a balanced mix of left and right or primarily centrist.

Subscribe to unlock this story

We really don't like cutting you off, but you've reached your monthly limit. At just $3/month or $30/year, subscriptions are how we keep this project going. Start your free 7-day trial today!

Get Started

No highlights available for this story.

Updated: Nov 26th, 2024, 10:03 PM ET

Summary

A summary of the key points of this story verified across multiple sources.

On November 26, 2024, the Biden administration proposed a $35 billion plan to cover anti-obesity drugs like Wegovy and Zepbound under Medicare and Medicaid, potentially benefiting millions. However, the rule, requiring Congressional approval, faces skepticism from incoming Trump administration officials, particularly Robert F. Kennedy Jr., who opposes the drugs. While a bipartisan coalition supports the initiative, concerns regarding its high cost and the necessity of price negotiations with manufacturers persist among some lawmakers.

Perspectives

Compare opinions on this story from liberal (Left), conservative (Right) or center-leaning news organizations.

No center-leaning sources available for this story.

History

A summary of how this story has evolved over the last 24 hours.